만성 폐쇄성 폐질환 치료제 시장 규모, 점유율 및 성장 분석(COPD 유형별, 약제 클래스별, 투여 경로별, 환자 속성별, 유통 채널별, 지역별) : 산업 예측(2025-2032년)
Chronic Obstructive Pulmonary Disease Drugs Market Size, Share, and Growth Analysis, By COPD Type, By Drug Class, By Administration Type, By Patient Demographics, By Distribution Channel, By Region - Industry Forecast 2025-2032
상품코드:1758554
리서치사:SkyQuest
발행일:2025년 06월
페이지 정보:영문 192 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 만성 폐쇄성 폐질환 치료제 시장 규모는 2023년 75억 달러로 평가되었으며, 2024년 79억 5,000만 달러에서 2032년에는 126억 7,000만 달러로 성장해 예측기간 중(2025-2032년) CAGR은 6.0%를 나타낼 전망입니다.
세계의 만성 폐쇄성 폐질환 치료제 시장은 인지도 향상, 질병 유병률 상승, 조기 진단 및 치료에 대한 관심 증가로 인해 큰 성장을 이루고 있습니다. 대기오염 등의 요인에 의해 야기되는 진행성 호흡기 질환이며, 특히 도시나 개발도상국에서 급증하고 있습니다. 또한 조기 발견 및 인식을 촉진하는 공중 보건 이니셔티브와 지원 정책도 이 시장을 견인하고 있습니다. 의료 시스템이 만성 질환 관리를 선호하는 동안, 만성 폐쇄성 폐질환 치료제 시장은 호흡기 치료제 중에서도 중요한 부문입니다.
목차
서론
분석 목적
시장 범위
정의
분석 기법
정보 조달
2차·1차 데이터의 수법
시장 규모 예측
시장의 상정과 제약
주요 요약
시장 개요와 전망
수급 동향의 분석
부문별 기회 분석
시장 역학과 전망
시장 개요
시장 규모
시장 역학
성장 촉진요인과 기회
성장 억제요인과 과제
Porter's Five Forces 분석
시장의 주요 인사이트
주요 성공 요인
경쟁도
주요 투자 기회
시장 생태계
시장 매력도 지수(2024년)
PESTEL 분석
거시경제지표
밸류체인 분석
가격 분석
사례 연구
세계의 만성 폐쇄성 폐질환 치료제 시장 규모·CAGR : COPD 유형별(2025-2032년)
시장 개요
만성 기관지염
폐기종
세계의 만성 폐쇄성 폐질환 치료제 시장 규모·CAGR : 약제 클래스별(2025-2032년)
시장 개요
병용 요법
기관지 확장제
코르티코스테로이드
포스포디에스테라제 4형 억제제
점액 동역학
기타
세계의 만성폐쇄성 폐질환 치료제 시장 규모·CAGR : 투여 방법별(2025-2032년)
시장 개요
흡입제
경구제
주사제
세계의 만성 폐쇄성 폐질환 치료제 시장 규모·CAGR : 환자 속성별(2025-2032년)
시장 개요
연령
성별
질병의 중증도
세계의 만성 폐쇄성 폐질환 치료제 시장 규모·CAGR : 유통 채널별(2025-2032년)
시장 개요
병원 약국
소매 약국
온라인 약국
세계의 만성 폐쇄성 폐질환 치료제 시장 규모·CAGR(2025-2032년)
북미
미국
캐나다
유럽
독일
스페인
프랑스
영국
이탈리아
기타 유럽
아시아태평양
중국
인도
일본
한국
기타 아시아태평양
라틴아메리카
브라질
기타 라틴아메리카
중동 및 아프리카
GCC 국가
남아프리카
기타 중동 및 아프리카
경쟁 구도
상위 5개사 비교
주요 기업의 시장 포지셔닝(2024년)
주요 기업이 채용한 전략
시장의 최근 동향
주요 기업의 시장 점유율(2024년)
주요 기업 프로파일
기업 개요
제품 포트폴리오 분석
부문별 점유율 분석
수익 대 전년 비교(2022-2024년)
주요 기업 프로파일
AstraZeneca Plc
Boehringer Ingelheim International GmbH
Cadila Pharmaceuticals Ltd.
CHIESI Farmaceutici SpA
Cipla Inc.
Exela Pharma Sciences LLC
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd.
Innoviva, Inc.
Lupin Ltd.
Merck and Co. Inc.
Mundipharma International Ltd.
Novartis AG
Philip Morris International Inc.
SHIONOGI Co. Ltd.
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Theravance Biopharma Inc.
Vertex Pharmaceuticals Inc.
Viatris Inc.
결론과 권고
KTH
영문 목차
영문목차
Global Chronic Obstructive Pulmonary Disease Drugs Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 7.95 billion in 2024 to USD 12.67 billion by 2032, growing at a CAGR of 6.0% during the forecast period (2025-2032).
The global chronic obstructive pulmonary disease (COPD) drugs market is experiencing significant growth due to increasing awareness, rising disease prevalence, and a heightened focus on early diagnosis and treatment. COPD, a progressive respiratory condition primarily caused by factors such as cigarette smoke and air pollution, is escalating, particularly in urban areas and developing nations. As a result, the demand for effective pharmaceuticals that enhance lung function and manage symptoms is growing, contributing to reduced hospitalization rates. Innovative combination therapies and advanced inhalation technologies are gaining traction, further fueling market expansion. Additionally, public health initiatives promoting early detection and awareness, alongside supportive policies, are driving this market. As healthcare systems prioritize chronic disease management, the COPD drugs market remains a critical segment within respiratory therapeutics.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Chronic Obstructive Pulmonary Disease Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Chronic Obstructive Pulmonary Disease Drugs Market Segments Analysis
Global Chronic Obstructive Pulmonary Disease Drugs Market is segmented by COPD Type, Drug Class, Administration Type, Patient Demographics, Distribution Channel and region. Based on COPD Type, the market is segmented into Chronic Bronchitis and Emphysema. Based on Drug Class, the market is segmented into Combination Therapy, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitor, Mucokinetics and Others. Based on Administration Type, the market is segmented into Inhalation Devices, Oral Medications and Injectable Formulations. Based on Patient Demographics, the market is segmented into Age, Gender and Disease Severity. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Chronic Obstructive Pulmonary Disease Drugs Market
The global market for chronic obstructive pulmonary disease (COPD) drugs is significantly influenced by the increasing prevalence of the condition, which affected approximately 212.3 million individuals worldwide in 2019 and resulted in 3.3 million deaths. In the United States, 6.6% of adults were diagnosed with COPD in 2018. The growing awareness of this disease, coupled with initiatives such as COPD Awareness Month, is anticipated to propel market growth by fostering early diagnosis and advancing treatment options. These efforts aim to enhance patients' quality of life, thereby driving demand for effective COPD medications globally.
Restraints in the Global Chronic Obstructive Pulmonary Disease Drugs Market
The global market for chronic obstructive pulmonary disease (COPD) drugs faces significant challenges due to various side effects associated with these medications. Adverse effects such as oral infections, bruising, and hoarseness can deter patient adherence and impede overall market growth. Although inhaled steroids, including Fluticasone, are effective in reducing the frequency of exacerbations, they can also heighten the risk of infections. Moreover, COPD drugs may lead to severe complications, such as depression, cardiovascular problems, pulmonary hypertension, and, in certain instances, lung cancer, which negatively affects patient outcomes and poses additional barriers for manufacturers in this sector.
Market Trends of the Global Chronic Obstructive Pulmonary Disease Drugs Market
The Global Chronic Obstructive Pulmonary Disease (COPD) Drugs market is witnessing a significant trend towards the emergence of biologics and personalized medicine. Innovative therapies like AstraZeneca's Fasenra are revolutionizing treatment approaches by precisely targeting the inflammation associated with COPD, thereby enhancing patient outcomes. This trend reflects a broader shift towards precision medicine, where treatments are tailored to individual patient profiles, reducing systemic side effects and improving efficacy. As awareness of COPD increases and the demand for effective management options rises, the integration of biologic therapies is expected to drive market growth and reshape therapeutic strategies globally in the coming years.
Table of Contents
Introduction
Objectives of the Study
Scope of the Report
Definitions
Research Methodology
Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations
Executive Summary
Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis
Market Dynamics & Outlook
Market Overview
Market Size
Market Dynamics
Drivers & Opportunities
Restraints & Challenges
Porters Analysis
Competitive rivalry
Threat of substitute
Bargaining power of buyers
Threat of new entrants
Bargaining power of suppliers
Key Market Insights
Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Global Chronic Obstructive Pulmonary Disease Drugs Market Size by COPD Type & CAGR (2025-2032)
Market Overview
Chronic Bronchitis
Emphysema
Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Drug Class & CAGR (2025-2032)
Market Overview
Combination Therapy
Bronchodilators
Corticosteroids
Phosphodiesterase Type 4 Inhibitor
Mucokinetics
Others
Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Administration Type & CAGR (2025-2032)
Market Overview
Inhalation Devices
Oral Medications
Injectable Formulations
Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Patient Demographics & CAGR (2025-2032)
Market Overview
Age
Gender
Disease Severity
Global Chronic Obstructive Pulmonary Disease Drugs Market Size by Distribution Channel & CAGR (2025-2032)
